Infliximab does not increase the risk of early postoperative complications in UC patients after a three-stage restorative proctocolectomy with IPAA
Requires Subscription PDF

Keywords

infliximab
postoperative complications
ulcerative colitis
adult
gastrointestinální látky
lidé
lidé středního věku
mladiství
monoclonal antibodies
mužské pohlaví
retrospective study
riziko - zhodnocení
staří
time factors
TNF-alfa
ženské pohlaví
břišní absces
heart failure
hodnocení rizik
ileal pouch-anal anastomosis
infekce chirurgické rány
mladý dospělý
multivariační analýza
netěsnost anastomózy
poměr šancí
předoperační péče
proktokolektomie rekonstrukční
regresní analýza
retrospektivní studie
trojdobá operace
tromboembolie
ulcerózní kolitida

Abstract

Introduction and aim: Patients with ulcerative colitis (UC) treated with infliximab (IFX) preoperatively are theoretically at increased risk of complications after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). The aim was to compare the occurrence of early postoperative complications among patients treated and not treated with IFX.

Methods: A retrospective analysis of different types of early postoperative complications in UC patients treated and not treated with IFX.

Results: Between January 2006 and December 2012,138 UC patients underwent surgical therapy. Of these patients, 108 had restorative proctocolectomy and IPAA. Forty-seven patients received IFX preoperatively (IFX group), while 61 did not receive any IFX (No-IFX group). In total, early complications occurred in 40.4% of patients in the IFX group, and in 44.3% in the No-IFX group. Using logistic regression analysis, no statistically significant difference was found in the occurrence of any particular type of both surgical and non-surgical complications.

Conclusion: We did not observe an increased occurrence of early postoperative complications in UC patients after a three-stage restorative proctocolectomy with IPAA.

External Links

Requires Subscription PDF